Phio Pharmaceuticals
PHIO
8 hedge funds and large institutions have $218K invested in Phio Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 0 increasing their positions, 3 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more funds holding
Funds holding: 6 → 8 (+2)
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
24% less capital invested
Capital invested by funds: $285K → $218K (-$67K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$84.7K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$50.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$28.8K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$127K |
| 2 |
WS
Wedbush Securities
Los Angeles,
California
|
-$73K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$24.9K |
| 4 |
VFA
Valeo Financial Advisors
Carmel,
Indiana
|
-$1K |
| 5 |
HSBC Holdings
London,
United Kingdom
|
-$509 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $77K | +$84.7K | +333 | New |
|
|
GCP
2
GSA Capital Partners
London,
United Kingdom
| $46K | +$50.1K | +197 | New |
|
|
3
Renaissance Technologies
New York
| $43K | -$127K | -499 | -73% |
|
|
4
Citadel Advisors
Miami,
Florida
| $26K | +$28.8K | +113 | New |
|
|
5
HSBC Holdings
London,
United Kingdom
| $24K | -$509 | -2 | -2% |
|
|
6
UBS Group
Zurich,
Switzerland
| $1K | -$24.9K | -98 | -95% |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $1K | +$1.27K | +5 | New |
|
|
WS
8
Wedbush Securities
Los Angeles,
California
| – | -$73K | -309 | Closed |
|
|
VFA
9
Valeo Financial Advisors
Carmel,
Indiana
| – | -$1K | -2 | Closed |
|
PHIO Hedge Fund Activity: Q3 2020 in Review
8 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q3 2020, worth a combined $218K — down 24% from $285K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PHIO positions and 2 closed out — a net gain of 2 holders — while 0 added to existing stakes and 3 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $84.7K. The largest seller was Renaissance Technologies, cutting an estimated $127K.
- 8 institutional investors held Phio Pharmaceuticals (PHIO) as of Q3 2020, up from 6 in Q2 2020.
- Funds reported $218K of Phio Pharmaceuticals stock for Q3 2020, down 24% quarter-over-quarter.
- 4 funds opened new Phio Pharmaceuticals positions in Q3 2020 and 2 closed out, a net change of +2 holders.
- The largest Phio Pharmaceuticals buyer in Q3 2020 was Virtu Financial, an estimated $84.7K added.
- The largest Phio Pharmaceuticals seller in Q3 2020 was Renaissance Technologies, an estimated $127K sold.
Based on aggregated 13F filings for Q3 2020.